Search

Your search keyword '"Petersen, Lars J."' showing total 292 results
Start Over Author "Petersen, Lars J." Language english
292 results on '"Petersen, Lars J."'

6. Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group

Author

Lecouvet, Frédéric E, Oprea-Lager, Daniela E, Liu, Yan, Ost, Piet, Bidaut, Luc, Collette, Laurence, Deroose, Christophe M, Goffin, Karolien, Herrmann, Ken, Hoekstra, Otto S, Kramer, Gem, Lievens, Yolande, Lopci, Egesta, Pasquier, David, Petersen, Lars J, Talbot, Jean-Noël, Zacho, Helle, Tombal, Bertrand, and deSouza, Nandita M

Published
2018
Full Text
View/download PDF

23. Observer experience and accuracy of 18F-sodium-fluoride PET/CT for the diagnosis of bone metastases in prostate cancer

Author

Zacho, Helle D., Ravn, Søren, Ejlersen, June A., Fledelius, Joan, Dolliner, Peter, Nygaard, Sofie T., Holdgaard, Paw C., Lauridsen, Jeppe F., Haarmark, Christian, Hendel, Helle W., and Petersen, Lars J.

Subjects
Male, Bone Neoplasms/diagnostic imaging, Fluorine Radioisotopes, Sodium, Prostatic Neoplasms, Bone Neoplasms, General Medicine, Fluorides, Positron Emission Tomography Computed Tomography, Prostatic Neoplasms/diagnostic imaging, Humans, Sodium Fluoride, Radiology, Nuclear Medicine and imaging, Prospective Studies, Positron Emission Tomography Computed Tomography/methods
Abstract

OBJECTIVE: To evaluate the diagnostic accuracy of observers with different levels of experience in reading 18F-sodium fluoride (NaF) PET/CT images for the diagnosis of bone metastases in prostate cancer (PCa) patients.METHODS: Nine observers with varying NaF PET/CT experience, ranging from no experience to 2000+ examinations, evaluated 211 NaF PET/CT scans from PCa patients participating in one of four prospective trials. Each observer evaluated each NaF PET/CT on a patient level using a trichotomous scale: M0 (no bone metastases), Me (equivocal for bone metastases) and M1 (bone metastases). Subsequently, a dichotomous evaluation was conducted (M0/M1). The final diagnosis was retrieved from the original study. For each observer, ROC curves and the diagnostic accuracy were calculated based on dichotomous and trichotomous scales; in the latter case, Me was first regarded as M1 and then M0.RESULTS: Across all experience levels, the sensitivity, specificity and accuracy using the dichotomous scale ranged from 0.81 to 0.89, 0.93 to 1.00 and 0.91 to 0.94, respectively. Employing the trichotomous scale, novice and experienced observers chose Me in up to 20 vs. 10% of cases, respectively. Considering Me as M0, the sensitivity, specificity and accuracy ranged from 0.78 to 0.89, 0.95 to 1.00 and 0.91 to 0.95, respectively. Considering Me as M1, the sensitivity, specificity and accuracy ranged from 0.86 to 0.92, 0.71 to 0.96 and 0.77 to 0.94, respectively.CONCLUSION: Novice observers used the equivocal option more frequently than observers with NaF PET/CT experience. However, on the dichotomous scale, all observers exhibited high and satisfactory accuracy for the detection of bone metastases, making NaF PET/CT an effective imaging modality even in unexperienced hands.

Published
2022
Full Text
View/download PDF

34. Response evaluation of bone metastasis in prostate cancer:Preliminary comparison of computerized bone scan index versus standardized clinical criteria

Author

Petersen, Lars J., Gade, Michael, Fonager, Randi F., Albertsen, Signe, Fledelius, Joan, Ejlersen, June A., Christensen, Mette H., Aleksyniene, Ramune, and Zacho, Helle D.

Subjects
Prostate cancer, Bone metastases, Response evaluation, Prostate Cancer Working Group 2, Bone scintigraphy, Bone scan index (BSI)
Abstract

OBJECTIVE: The correlation between the computer-assisted bone scan index (BSI) responses versus clinical response classification if bone metastases in prostate cancer patients are not clear. We compared changes in BSI with Prostate Cancer Working Group-3 (PCWG3) and MD Anderson (MDA) criteria. MATERIALS AND METHODS: Fifty-six consecutive patients with at least two bone scans (BS) within 12 months were included, who had BS before and after treatment with the same anticancer agent. RESULTS: Progressive disease (PD) by PCWG3 criteria was seen in 28% of the cases (median BSI increased by 1.69 units) versus non-PD in 72% (BSI change -0.13). MDAnderson showed PD in 34% (BSI increase 0.49), 45% stable disease (BSI change 0.00), and 20% partial responses (BSI decrease 1.44). Absolute BSI changes differed significantly among response categories by PCWG3 and MDA criteria (both P0/≤0 and >0.3/≤0.3 BSI units) showed a significant correlation with PCWG3 and MDA criteria (all P

Published
2021
Full Text
View/download PDF

35. The clinical consequences of routine 68Ga-PSMA-11 PET/CT in patients with newly diagnosed prostate cancer, ISUP grade 5 and no metastases based on standard imaging – preliminary results.

Author

Zacho, Helle D., Nalliah, Surenth, Petersen, Astrid, and Petersen, Lars J.

Subjects
PROSTATE cancer, RADIONUCLIDE imaging, LYMPHATIC metastasis, BONE metastasis, METASTASIS, PALLIATIVE treatment
Abstract

To evaluate the clinical consequences of prostate specific membrane antigen (PSMA) PET/CT for primary staging in patients with ISUP grade 5 (Gleason score ≥9) prostate cancer (PCa), and no definitive distant metastases based on standard imaging. At our tertial referral center, PSMA PET/CT became standard of care from August 2018 for primary staging of prostate cancer given the following criteria: (1) no prior treatment for prostate cancer, (2) ISUP grade 5, (3) no definitive metastases on standard imaging (contrast enhanced CT and bone scintigraphy), and (4) deemed suitable for treatment with curative intent based on comorbidity and life expectancy. We present the preliminary results of first six months recruitment with 12 months of follow-up. Forty-eight patients (mean age 69 years, median PSA 13.0 ng/mL, 20 patients with locally advanced PCa) were included. CT was positive in pelvic lymph nodes in two patients, bone scintigraphy was equivocal in three patients. PSMA PET/CT showed pathological uptake outside the prostatic bed in 22 patients (46%) of which 13 patients (27%) showed lesions confined to regional lymph nodes, and nine patients (19%) showed nonregional lymph node metastases and/or bone metastases. PSMA PET/CT changed the treatment strategy from curatively intended treatment to palliative treatment in 18 patients (38%) PMSA PET/CT revealed pathological uptake in a large proportion of high-risk patients at primary staging among patients with no definite metastases on standard imaging leading to change of patient management in 38% of the patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

38. Influence of Prior Imaging Information on Diagnostic Accuracy for Focal Skeletal Processes—A Retrospective Analysis of the Consistency between Biopsy-Verified Imaging Diagnoses.

Author

Lange, Mine Benedicte, Petersen, Lars J., Lausen, Mads, Bruun, Niels Henrik, Nielsen, Michael Bachmann, and Zacho, Helle D.

Subjects
*DIAGNOSTIC imaging, *ACCURACY of information, *RETROSPECTIVE studies, *DIAGNOSTIC errors, *DIAGNOSIS
Abstract

Introduction: Comparing imaging examinations with those previously obtained is considered mandatory in imaging guidelines. To our knowledge, no studies are available on neither the influence, nor the sequence, of prior imaging and reports on diagnostic accuracy using biopsy as the reference standard. Such data are important to minimize diagnostic errors and to improve the preparation of diagnostic imaging guidelines. The aim of our study was to provide such data. Materials and methods: A retrospective cohort of 216 consecutive skeletal biopsies from patients with at least 2 different imaging modalities (X-ray, CT and MRI) performed within 6 months of biopsy was identified. The diagnostic accuracy of the individual imaging modality was assessed. Finally, the possible influence of the sequence of imaging modalities was investigated. Results: No significant difference in the accuracy of the imaging modalities was shown, being preceded by another imaging modality or not. However, the sequence analyses indicate sequential biases, particularly if MRI was the first imaging modality. Conclusion: The sequence of the imaging modalities seems to influence the diagnostic accuracy against a pathology reference standard. Further studies are needed to establish evidence-based guidelines for the strategy of using previous imaging and reports to improve diagnostic accuracy. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

39. The frequency of thyroid incidental findings and risk of malignancy detected by 68Ga-labeled prostate-specific membrane antigen PET/CT in prostate cancer

Author

Gossili, Farid, Petersen, Lars J, and Zacho, Helle D

Abstract

OBJECTIVE: Gallium-68-prostate-specific membrane antigen positron emission tomography/computed tomography (68Ga-PSMA PET/CT) has become a well-established imaging method for the evaluation of patients with prostate cancer. However, several cases have revealed PSMA uptake in a large variety of conditions other than prostate cancer. Prostate-specific membrane antigen uptake in thyroid cancer has also been reported. The aim of the present study was to systematically investigate the prevalence and clinical significance of thyroid incidental findings in patients undergoing 68Ga-PSMA PET/CT.MATERIALS AND METHODS: We retrospectively identified all patients referred for 68Ga-PSMA PET/CT at the Department of Nuclear Medicine, Aalborg University Hospital, Denmark between May 2015 and May 2019. Patients with increased PSMA uptake in the thyroid gland were included in the analysis. Follow-up included imaging, biochemical, and/or histopathological collected over six months.RESULTS: A total of 341 patients were included. Increased 68Ga-PSMA uptake in the thyroid gland was observed in 13 patients (4%). Focal uptake was observed in seven patients, diffuse uptake in five patients and mixed focal and diffuse uptake in one patient. Malignancy was verified in two patients (2/13 patients, 15%), both patients with focal PSMA uptake.CONCLUSION: Gallium-68-PSMA thyroid incidental findings are rare in prostate cancer patients. However, cases of focal PSMA uptake in the thyroid gland should be further investigated, as these findings may represent metastatic or primary malignancy of the thyroid gland.

Published
2020
Full Text
View/download PDF

49. Validity of negative bone biopsy in suspicious bone lesions.

Author

Lange, Mine B, Petersen, Lars J, Nielsen, Michael B, and Zacho, Helle D

Subjects
*CANCER cells, *BIOPSY, *BONE metastasis, *STANDARD deviations, *BONE cells, *CALCIFICATIONS of the breast
Abstract

Background: The presence of malignant cells in bone biopsies is considered gold standard to verify occurrence of cancer, whereas a negative bone biopsy can represent a false negative, with a risk of increasing patient morbidity and mortality and creating misleading conclusions in cancer research. However, a paucity of literature documents the validity of negative bone biopsy as an exclusion criterion for the presence of skeletal malignancies. Purpose: To investigate the validity of a negative bone biopsy in bone lesions suspicious of malignancy. Material and Method: A retrospective cohort of 215 consecutive targeted non-malignant skeletal biopsies from 207 patients (43% women, 57% men, median age 64, and range 94) representing suspicious focal bone lesions, collected from January 1, 2011, to July 31, 2013, was followed over a 2-year period to examine any additional biopsy, imaging, and clinical follow-up information to categorize the original biopsy as truly benign, malignant, or equivocal. Standard deviations and 95% confidence intervals were calculated. Results: 210 of 215 biopsies (98%; 95% CI 0.94–0.99) showed to be truly benign 2 years after initial biopsy. Two biopsies were false negatives (1%; 95% CI 0.001–0.03), and three were equivocal (lack of imaging description). Conclusion: Our study documents negative bone biopsy as a valid criterion for the absence of bone metastasis. Since only 28% had a confirmed diagnosis of prior cancer and not all patients received adequately sensitive imaging, our results might not be applicable to all cancer patients with suspicious bone lesions. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results